Asia Beat: Blazing the biosimilar trail the Korean way
This article was originally published in Scrip
Executive Summary
The first approval worldwide of a monoclonal antibody under formal biosimilar guidelines - infliximab in South Korea in late July - has whipped up industry interest in the country's biosimilars capabilities, at least if the hits on Scrip's news article are anything to go by.